Despite the fact that the benefit of cholinesterase inhibitors have been established by numerous studies [4,5] and that they are a recommended treatment for AD [6], physicians may hesitate to treat patients accordingly given drug acquisition cost considerations [7]. This evidence concerns the gene BCHE and Alzheimer disease.